Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivit...( Current and Emerging Drugs Will Not S...),Health

Current and Emerging Drugs Will Not Surpass Vyvanse as the Clinical Gold Standard, According to a New Report From Decision Resources

WALTHAM, Mass., Jan. 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that physicians indicate there is an unmet need for a safe and effective nonstimulant therapy approved for adult attention-deficit/hyperactivity disorder (ADHD) with no risk of suicidal ideation. Such a drug has potential to earn a 25 percent patient share of the drug treated adult ADHD population, according to surveyed U.S. psychiatrists. In contrast, in Europe, such an agent would earn a markedly higher patient share of 40 percent, according to surveyed European psychiatrists.

This difference in patient share likely reflects U.S. physicians' reasonably high level of satisfaction with currently-available psychostimulants, with which they have decades of clinical experience, despite their disadvantages of abuse-liability and prescribing restrictions. Conversely, European physicians have to contend with greater prescribing restrictions, fewer treatment options, and are more averse to stimulants' risk of abuse than their U.S. counterparts. As a result, physicians would greatly welcome a safer and more effective nonstimulant alternative to Eli Lilly's Strattera as a first-line therapy for adult ADHD.

The new report entitled Attention-Deficit/Hyperactivity Disorder: Emerging Therapies Fall Short of Physicians' Expectations for Safer and More-Effective Nonstimulants finds that current and emerging drugs have not yet demonstrated substantial clinical advantages over Shire's Vyvanse, Decision Resources' 2008 clinical gold standard in the treatment of ADHD. According to interviewed physicians, none of the emerging therapies represent a major innovation in ADHD treatment or offer an overwhelmingly prefera
'/>"/>